Doxorubicin-induced cardiac mitochondrionopathy

Area of Science:

• Cardiology
• Oncology
• Biochemistry

Background:

• Doxorubicin (Adriamycin) is a widely used chemotherapy drug for various cancers.
• Long-term doxorubicin treatment can lead to cumulative and irreversible dilated cardiomyopathy.
• The exact mechanisms of doxorubicin-induced cardiotoxicity are still debated.

Purpose of the Study:

• To review the evidence implicating cardiac mitochondria in doxorubicin cardiotoxicity.
• To discuss the role of mitochondria in free radical generation and cellular damage.
• To explore mitochondrial dysfunction in calcium regulation and energy failure.

Main Methods:

• This is a review article, synthesizing existing research.
• Evidence from studies on doxorubicin's redox cycling and free radical generation is discussed.
• Focus is placed on subcellular targets within the heart.

Main Results:

• Doxorubicin undergoes redox cycling, generating free radicals that cause cellular damage.
• Cardiac mitochondria are identified as primary sites for free radical generation.
• Mitochondria are implicated in impaired calcium regulation and bioenergetic failure.

Conclusions:

• Cardiac mitochondria are key intracellular targets in doxorubicin-induced cardiotoxicity.
• Mitochondrial dysfunction contributes significantly to the development of dilated cardiomyopathy.
• Understanding these mechanisms is crucial for mitigating doxorubicin's cardiac side effects.